<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03555864</url>
  </required_header>
  <id_info>
    <org_study_id>Local-PC-2017-2</org_study_id>
    <nct_id>NCT03555864</nct_id>
  </id_info>
  <brief_title>Intravenous Access Using Infrared Laser</brief_title>
  <acronym>AccuV</acronym>
  <official_title>Peripheral Intravenous Cannulation With Support of Infrared Laser Vein Viewing System in Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peripheral venous access is a prerequisite for anesthesiological for surgical patients.It is
      often difficult to establish and potentially painful in obese patients (Body mass Index &gt;
      35). AV300 uses near infrared laser light to improve visibility of peripheral veins and could
      help cannulating them. The aim of this study was to examine if use of Accuvein(®) AV300 vein
      viewer could facilitate venous cannulation in obese patients (surgical and obstetric).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 6, 2017</start_date>
  <completion_date type="Actual">July 4, 2019</completion_date>
  <primary_completion_date type="Actual">November 30, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>success for second intravenous line using infra red</measure>
    <time_frame>1 day</time_frame>
    <description>number of attempts</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time</measure>
    <time_frame>1 day</time_frame>
    <description>time in second for second intravenous access</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">100</enrollment>
  <condition>Obesity, Morbid</condition>
  <condition>Obstetric Anesthesia Problems</condition>
  <arm_group>
    <arm_group_label>Obese</arm_group_label>
    <description>Patients need two intravenous access with infra red</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>infrared transluminescent device</intervention_name>
    <description>use of infra red for venous access for second intravenous access</description>
    <arm_group_label>Obese</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients that need second intravenous access for surgery or obstetric
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  &gt; 18 years

          -  surgery that need double intravenous perfusion

        Exclusion Criteria:

          -  &lt; 18 years

          -  body mass index&lt; 35

          -  refusal

          -  minor surgery that need only one intravenous access
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>jean-yves Lefrant, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospitalier Universitaire de Nīmes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nîmes</city>
        <state>Gard</state>
        <zip>30 000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>December 30, 2017</study_first_submitted>
  <study_first_submitted_qc>June 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2018</study_first_posted>
  <last_update_submitted>July 4, 2019</last_update_submitted>
  <last_update_submitted_qc>July 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire de Nīmes</investigator_affiliation>
    <investigator_full_name>Philippe Cuvillon</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

